Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

U.S. is closer to first biosimilar

FDA officials see no difference between Neupogen and the biosimilar version.

Earlier this week documents from FDA reviewers decided that there are "no clinically meaningful difference" between Amgen's Neupogen, and Sandoz's biosimilar version, the Wall Street Journal reported.

Neupogen is used during chemotherapy to fight off infections.

According to the article, an FDA advisory committee is expected to be meeting Jan. 7, to review a marketing application filed for the drug.

Their decision could be market-changing.

"If approved, the Sandoz version would become the first biosimilar in the U.S., by way of a regulatory pathway that was created for these medicines three years ago," according to the article.

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO